title: [Biomarker of dementia: clinical and preclinical diagnosis].
abstract: Recent advances in biomarker studies on dementia are summarized here. CSF Abeta40, Abeta42, total tau and phosphorylated tau are most sensitive biomarkers for diagnosis of Alzheimer's disease (AD) and prediction of onset of AD from mild cognitive impairment (MCI). Based on this progress, new diagnostic criteria for AD, MCI and preclinical AD were proposed by National Institute of Aging (NIA) and Alzheimer' s Association. In these new criteria, progress in biomarker identification and amyloid imaging studies in the past 10 years have added critical information. Huge contributions of basic and clinical studies have established clinical evidence supporting these markers. Based on this progress, essential therapy for cure of AD is urgently expected.
authors.affiliation: Department of Neurology, Hirosaki University Graduate School of Medicine.
authors.forename: Mikio
authors.initials: M
authors.lastname: Shoji
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis; D016229:Amyloid beta-Peptides / Q000032:analysis* / Q000097:blood / Q000134:cerebrospinal fluid; D015415:Biomarkers; D003704:Dementia / Q000175:diagnosis*; D006801:Humans; D010446:Peptide Fragments / Q000032:analysis* / Q000097:blood / Q000134:cerebrospinal fluid; D016875:tau Proteins / Q000134:cerebrospinal fluid
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C538897:amyloid beta-protein (40-42); D016875:tau Proteins